(Q45709923)

15 December 2017

title

Prophylaxis against respiratory syncytial virus (RSV), varicella, and pneumococcal infections: Economic-based decision-making (English)

1 reference

15 December 2017

Prophylaxis against respiratory syncytial virus (RSV), varicella, and pneumococcal infections: economic-based decision-making (English)

1 reference

https://api.crossref.org/works/10.1067/S0022-3476(03)00512-2

1 April 2024

1 reference

David R. Strutton

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14615715

1 April 2024

Paul E. Stang

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A14615715

1 April 2024

language of work or name

English

0 references

publication date

1 November 2003

1 reference

full work available at URL

15 December 2017

https://api.elsevier.com/content/article/PII:S0022347603005122?httpAccept=text/xml

1 reference

https://api.crossref.org/works/10.1067/S0022-3476(03)00512-2

https://api.elsevier.com/content/article/PII:S0022347603005122?httpAccept=text/plain

1 April 2024

1 reference

https://api.crossref.org/works/10.1067/S0022-3476(03)00512-2

The Journal of Pediatrics

1 April 2024

published in

1 reference

15 December 2017

volume

143

1 reference

15 December 2017

issue

5 Suppl

1 reference

15 December 2017

page(s)

S157-62

1 reference

The cost of prematurity: a case-control study of twins vs singletons

15 December 2017

cites work

1

1 reference

https://api.crossref.org/works/10.1067/S0022-3476(03)00512-2

Cost-effectiveness of care for very low birth weight infants

1 April 2024

2

1 reference

https://api.crossref.org/works/10.1067/S0022-3476(03)00512-2

1 April 2024

time preference

3

1 reference

https://api.crossref.org/works/10.1067/S0022-3476(03)00512-2

Prevention of varicella: Recommendations of the Advisory Committee on Immunization Practices (ACIP). Centers for Disease Control and Prevention

1 April 2024

7

1 reference

https://api.crossref.org/works/10.1067/S0022-3476(03)00512-2

1 April 2024

Varicella Vaccine Update

8

1 reference

https://api.crossref.org/works/10.1067/S0022-3476(03)00512-2

A benefit-cost analysis of a childhood varicella vaccination programme

1 April 2024

9

1 reference

https://api.crossref.org/works/10.1067/S0022-3476(03)00512-2

Cost-effectiveness of a routine varicella vaccination program for US children

1 April 2024

10

1 reference

https://api.crossref.org/works/10.1067/S0022-3476(03)00512-2

Childhood vaccination against chickenpox: an analysis of benefits and costs

1 April 2024

11

1 reference

https://api.crossref.org/works/10.1067/S0022-3476(03)00512-2

Projected cost-effectiveness of pneumococcal conjugate vaccination of healthy infants and young children

1 April 2024

12

1 reference

https://api.crossref.org/works/10.1067/S0022-3476(03)00512-2

Policy Statement: Recommendations for the Prevention of Pneumococcal Infections, Including the Use of Pneumococcal Conjugate Vaccine (Prevnar), Pneumococcal Polysaccharide Vaccine, and Antibiotic Prophylaxis

1 April 2024

14

1 reference

https://api.crossref.org/works/10.1067/S0022-3476(03)00512-2

American Academy of Pediatrics. Committee on Infectious Diseases. Technical report: prevention of pneumococcal infections, including the use of pneumococcal conjugate and polysaccharide vaccines and antibiotic prophylaxis

1 April 2024

15

1 reference

https://api.crossref.org/works/10.1067/S0022-3476(03)00512-2

Efficacy, safety and immunogenicity of heptavalent pneumococcal conjugate vaccine in children. Northern California Kaiser Permanente Vaccine Study Center Group

1 April 2024

16

1 reference

https://api.crossref.org/works/10.1067/S0022-3476(03)00512-2

Assessing the potential cost effectiveness of pneumococcal vaccines in the US: methodological issues and current evidence

1 April 2024

17

1 reference

https://api.crossref.org/works/10.1067/S0022-3476(03)00512-2

Predicting cost-benefits before programs are started: looking at conjugate vaccine for invasive pneumococcal infections

1 April 2024

19

1 reference

https://api.crossref.org/works/10.1067/S0022-3476(03)00512-2

Immunogenicity of heptavalent pneumococcal conjugate vaccine in infants

1 April 2024

20

1 reference

https://api.crossref.org/works/10.1067/S0022-3476(03)00512-2

Evaluation of a pentavalent conjugated pneumococcal vaccine in toddlers

1 April 2024

21

1 reference

https://api.crossref.org/works/10.1067/S0022-3476(03)00512-2

Prevention of respiratory syncytial virus infections: indications for the use of palivizumab and update on the use of RSV-IGIV. American Academy of Pediatrics Committee on Infectious Diseases and Committee of Fetus and Newborn

1 April 2024

22

1 reference

https://api.crossref.org/works/10.1067/S0022-3476(03)00512-2

Bronchiolitis-associated hospitalizations among US children, 1980-1996.

1 April 2024

23

1 reference

https://api.crossref.org/works/10.1067/S0022-3476(03)00512-2

Respiratory syncytial virus: A continuing culprit and conundrum

1 April 2024

27

1 reference

https://api.crossref.org/works/10.1067/S0022-3476(03)00512-2

Respiratory syncytial virus in infants and children

1 April 2024

28

1 reference

https://api.crossref.org/works/10.1067/S0022-3476(03)00512-2

Risk of primary infection and reinfection with respiratory syncytial virus

1 April 2024

29

1 reference

https://api.crossref.org/works/10.1067/S0022-3476(03)00512-2

Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk Infants

1 April 2024

30

1 reference

https://api.crossref.org/works/10.1067/S0022-3476(03)00512-2

From the National Institute of Allergy and Infectious Diseases and the World Health Organization. Respiratory syncytial and parainfluenza viruses

1 April 2024

32

1 reference

https://api.crossref.org/works/10.1067/S0022-3476(03)00512-2

Cost-effectiveness of respiratory syncytial virus prophylaxis among preterm infants

1 April 2024

33

1 reference

https://api.crossref.org/works/10.1067/S0022-3476(03)00512-2

Respiratory syncytial virus and premature infants born at 32 weeks' gestation or earlier: hospitalization and economic implications of prophylaxis

1 April 2024

34

1 reference

https://api.crossref.org/works/10.1067/S0022-3476(03)00512-2

1 April 2024

Identifiers

1 reference

15 December 2017

1 reference